Facts and hopes in colorectal cancer immunotherapy Review
| Authors: | Foote, M. B.; Argilés, G.; Rousseau, B.; Segal, N. H. |
| Review Title: | Facts and hopes in colorectal cancer immunotherapy |
| Abstract: | Although a minority of colorectal cancers exhibit mismatch repair deficiency and associated sensitivity to immune checkpoint inhibitors (ICI), the vast majority of colorectal cancers arise in a tolerogenic microenvironment with mismatch repair proficiency, low tumor-intrinsic immunogenicity, and negligible immunotherapy responsiveness. Treatment strategies to augment tumor immunity with combination ICIs and chemotherapy have broadly failed in mismatch repair–proficient tumors. Similarly, although several small single-arm studies have shown that checkpoint blockade plus radiation or select tyrosine kinase inhibition may show improved outcomes compared with historical controls, this finding has not been clearly validated in randomized trials. An evolving next generation of intelligently engineered checkpoint inhibitors, bispecific T-cell engagers, and emerging CAR-T cell therapies may improve immunorecognition of colorectal tumors. Across these modalities, ongoing translational efforts to bet ter define patient populations and biomarkers associated with immune response, as well as combine biologically sound and mutually amplifying therapies, show promise for a new era of immunotherapy in colorectal cancer. ©2023 American Association for Cancer Research. |
| Keywords: | cancer chemotherapy; treatment response; unclassified drug; review; monotherapy; cancer radiotherapy; colorectal cancer; biological marker; cancer immunotherapy; immunoreactivity; immunoregulation; protein tyrosine kinase inhibitor; immune response; mismatch repair; immunogenicity; antigen recognition; tumor immunity; drug sensitivity; vasculotropin antibody; tumor microenvironment; clinical outcome; immune checkpoint inhibitor; cancer prognosis; pembrolizumab; obinutuzumab; immunological antineoplastic agent; tumor mutational burden; chimeric antigen receptor t-cell immunotherapy; cemiplimab; ro 7122290; sasanlimab; balstilimab; botensilimab; cibisatamab; favezelimab; favezelimab plus pembrolizumab; pf 07062119; regn 7075 |
| Journal Title: | Clinical Cancer Research |
| Volume: | 29 |
| Issue: | 20 |
| ISSN: | 1078-0432 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2023-10-15 |
| Start Page: | 4032 |
| End Page: | 4039 |
| Language: | English |
| DOI: | 10.1158/1078-0432.Ccr-22-2176 |
| PUBMED: | 37326624 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PDF -- MSK corresponding author is Neil Segal -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work